Despite this, we found that LRP inhibited increases in both galectin-9 and Tim-3 expression at 24 hours post-stroke, suggesting that inhibition of the galectin-9/Tim-3 pathway may be a target for stroke therapy. This evidence concerns the gene HAVCR2 and stroke disorder.